skip to main content

Title: A planning study investigating dual-gated volumetric arc stereotactic treatment of primary renal cell carcinoma

This is a planning study investigating the dosimetric advantages of gated volumetric-modulated arc therapy (VMAT) to the end-exhale and end-inhale breathing phases for patients undergoing stereotactic treatment of primary renal cell carcinoma. VMAT plans were developed from the end-inhale (VMATinh) and the end-exhale (VMATexh) phases of the breathing cycle as well as a VMAT plan and 3-dimensional conformal radiation therapy plan based on an internal target volume (ITV) (VMATitv). An additional VMAT plan was created by giving the respective gated VMAT plan a 50% weighting and summing the inhale and exhale plans together to create a summed gated plan. Dose to organs at risk (OARs) as well as comparison of intermediate and low-dose conformity was evaluated. There was no difference in the volume of healthy tissue receiving the prescribed dose for the planned target volume (PTV) (CI100%) for all the VMAT plans; however, the mean volume of healthy tissue receiving 50% of the prescribed dose for the PTV (CI50%) values were 4.7 (± 0.2), 4.6 (± 0.2), and 4.7 (± 0.6) for the VMATitv, VMATinh, and VMATexh plans, respectively. The VMAT plans based on the exhale and inhale breathing phases showed a 4.8% and 2.4% reduction in dose to 30more » cm{sup 3} of the small bowel, respectively, compared with that of the ITV-based VMAT plan. The summed gated VMAT plans showed a 6.2% reduction in dose to 30 cm{sup 3} of the small bowel compared with that of the VMAT plans based on the ITV. Additionally, when compared with the inhale and the exhale VMAT plans, a 4% and 1.5%, respectively, reduction was observed. Gating VMAT was able to reduce the amount of prescribed, intermediate, and integral dose to healthy tissue when compared with VMAT plans based on an ITV. When summing the inhale and exhale plans together, dose to healthy tissue and OARs was optimized. However, gating VMAT plans would take longer to treat and is a factor that needs to be considered.« less
Authors:
 [1] ;  [1] ;  [2] ;  [3] ;  [4] ;  [3] ;  [5] ;  [4] ;  [3]
  1. Radiation Therapy Services, Peter MacCallum Cancer Centre, Melbourne (Australia)
  2. Department of Physical Sciences, Peter MacCallum Cancer Centre, Melbourne (Australia)
  3. (Australia)
  4. Sir Peter MacCallum Department of Oncology, Melbourne University, Melbourne (Australia)
  5. School of Applied Sciences, Royal Melbourne Institute of Technology, Melbourne (Australia)
Publication Date:
OSTI Identifier:
22462430
Resource Type:
Journal Article
Resource Relation:
Journal Name: Medical Dosimetry; Journal Volume: 40; Journal Issue: 1; Other Information: Copyright (c) 2015 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.; Country of input: International Atomic Energy Agency (IAEA)
Country of Publication:
United States
Language:
English
Subject:
61 RADIATION PROTECTION AND DOSIMETRY; ANIMAL TISSUES; CARCINOMAS; COMPARATIVE EVALUATIONS; HAZARDS; INTEGRAL DOSES; KIDNEYS; PATIENTS; PLANNING; RADIOTHERAPY; RESPIRATION; THREE-DIMENSIONAL CALCULATIONS